(Q35184561)

7 August 2017

1 reference

title

Hepatotoxicity of antibiotics and antifungals (English)

1 reference

7 August 2017

0 references

1 reference

Michael Thiim

1

1 reference

PubMed ID

12879990

7 August 2017

Lawrence S Friedman

series ordinal

2

1 reference

7 August 2017

1 May 2003

1 reference

7 August 2017

Clinics in liver disease

1 reference

7 August 2017

7

1 reference

7 August 2017

381-99, vi-vii

1 reference

7 August 2017

2

1 reference

Drug-induced liver injury: mechanisms and test systems.

7 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

The natural history of histologically proved drug induced liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

1 reference

7 January 2021

Chronic cholestasis, paucity of bile ducts, red cell aplasia, and the Stevens-Johnson syndrome. An ampicillin-associated case

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Cholestatic hepatitis after dicloxacillin-sodium therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Cloxacillin-induced cholestasis.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Nafcillin-associated hepatotoxicity. Report of a case and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Antibiotic-associated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged, intrahepatic cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Flucloxacillin induced liver disease: histopathological findings at biopsy and autopsy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Oxacillin hepatitis. Two patients with liver biopsy, and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Oxacillin hepatotoxicity in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Adverse reactions to co-trimoxazole in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Systemic glutathione deficiency in symptom-free HIV-seropositive individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Amoxycillin/clavulanic acid (Augmentin)-induced intrahepatic cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Cholestatic hepatitis due to antibacterial combination of amoxicillin and clavulanic acid (augmentin)

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Cholestatic hepatitis due to an amoxycillin/clavulanic acid preparation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Amoxicillin-clavulanate potassium-associated cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Amoxicillin-clavulanic acid versus cefaclor in the treatment of urinary tract infections and their effects on the urogenital and rectal flora

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Criteria of drug-induced liver disorders. Report of an international consensus meeting

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

HLA association of amoxicillin-clavulanate--induced hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Tetracycline-induced fatty liver in nonpregnant patients. A report of six cases

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Tetracycline-associated fatty liver in the male. Report of an autopsied case

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

FATAL LIVER DISEASE AFTER INTRAVENOUS ADMINISTRATION OF TETRACYCLINE IN HIGH DOSAGE

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Liver reactions to oral low-dose tetracyclines

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: Possible role in microvesicular steatosis induced by this antibiotic

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Acute hepatic injury associated with minocycline

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Minocycline as a cause of drug-induced autoimmune hepatitis. Report of four cases and comparison with autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Acute hepatitis and exfoliative dermatitis associated with minocycline

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Minocycline-induced hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Norfloxacin-Induced Cholestatic Jaundice

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Fatal hepatic failure associated with ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Fulminant hepatic failure possibly related to ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Autoantibodies against a kidney--liver protein associated with quinolone-induced acute interstitial nephritis or hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Trovafloxacin hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Trovafloxacin-induced acute hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Chemical structure of erythromycin and hepatotoxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Allergic Hepatitis Caused by Propionyl Erythromycin Ester of Lauryl Sulfate

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Asymptomatic liver injury due to erythromycin stearate

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Hepatotoxicity of Erythromycin

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Erythromycin estolate and jaundice.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Hepatotoxicity to both erythromycin estolate and erythromycin ethylsuccinate

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Cholestatic hepatitis from erythromycin ethylsuccinate. Report of two cases

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Concentrations of erythromycin in serum and tonsil: comparison of the estolate and ethyl succinate suspensions

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Cholestatic and hepatocellular injury associated with erythromycin esters: report of nine cases

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

A prospective study on the incidence of liver function abnormalities in children receiving erythromycin estolate, erythromycin ethylsuccinate or penicillin V for treatment of pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Cholestatic hepatitis in a patient who received clarithromycin therapy for a Mycobacterium chelonae lung infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Clarithromycin-induced hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Hypersensitivity syndrome associated with azithromycin

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Fulminant hepatitis and fatal toxic epidermal necrolysis (Lyell disease) coincident with clarithromycin administration in an alcoholic patient receiving disulfiram therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Nitrofurantoin-induced chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

A nitrofurantoin-induced disorder simulating chronic active hepatitis. A case report

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Letter: Chronic active hepatitis induced by nitrofurantoin

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

1 reference

7 January 2021

Nitrofurantoin and chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Sulfonamide hepatic injury. Review of the literature and report of a case due to sulfamethoxazole

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Fansidar and hepatic granulomas

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Fatal hepatic necrosis due to pyrimethamine-sulfadoxine (Fansidar).

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Hypoprothrombinemia caused by cephalosporins

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Defects in vitamin K-dependent carboxylation associated with moxalactam treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Reversible ceftriaxone-associated biliary pseudolithiasis in children

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Ceftriaxone-associated biliary pseudolithiasis in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Apparent biliary pseudolithiasis during ceftriaxone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Icterus and febrile reactions in response to isonicotinic acid hydrazine; report of two cases and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Toxic hepatic necrosis (hepatitis) due to isoniazid: report of a case with cirrhosis and death due to hemorrhage from esophageal varices

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Toxic hepatitis with jaundice occuring in a patient treated with isoniazid

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Hepatitis after Isoniazid Administration

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

The Effect of Isoniazid on Transaminase Levels

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Toxic hepatitis with isoniazid and rifampin. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Disturbed hepatic function during isoniazid chemoprophylaxis. Monitoring the hepatic function of 427 hospital employees receiving isoniazid chemoprophylaxis for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Isoniazid toxicity. A prospective study in secondary chemoprophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Acetaminophen, isoniazid, and hepatic toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Severe acetaminophen toxicity in a patient receiving isoniazid

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Effect of rifampicin on liver function in man.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Hypersensitivity hepatitis due to pyrazinamide

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Hepatotoxicity caused by the combined action of isoniazid and rifampicin

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Hepatotoxicity possibly caused by amphotericin B.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Carbon monoxide poisoning

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Terbinafine-induced cholestatic liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Hepatitis associated with terbinafine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Terbinafine-associated hepatic injury

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

A randomized treatment duration-finding study of terbinafine in onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Hepatic reactions during ketoconazole treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Oral azole drugs as systemic antifungal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

Fatal acute hepatic necrosis due to fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900021-7

7 January 2021

10.1016/S1089-3261(03)00021-7

Identifiers

DOI

1 reference

7 August 2017

1 reference

PubMed ID

12879990